Using the novel antibody-drug conjugate, loncastuximab tesirine to treat patients with R/R diffuse large B-cell lymphoma

Treating patients with multiple myeloma in the real world

ASCEND final results: Acalabrutinib vs idelalisib plus rituximab or bendamustine plus rituximab in R/R CLL

KarMMa: Idecabtagene vicleucel in patients with r/r multiple myeloma

Combining the novel anti-CD47 antibody magrolimab with azacitidine in patients with TP53-mutant AML

New CAR T therapy for relapsed and refractory ALL

IKEMA: Carfilzomib and dexamethasone plus isatuximab for r/r multiple myeloma

LOW-PV interim analysis: Ropeginterferon versus phlebotomy in low-risk polycythemia vera

ANDROMEDA: Subcutaneous daratumumab plus cyclophosphamide, bortezomib and dexamethasone in newly-diagnosed AL amyloidosis

The NEUF study: Treatment of r/r Philadelphia chromosome-positive ALL with blinatumomab

BLIN-01: Blinatumomab for high-risk, Philadelphia chromosome-negative acute lymphoblastic leukaemia

MINDACT long-term results: 70-gene signature MammaPrint to guide adjuvant chemotherapy use in breast cancer